Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

• Autores principales: Ayca Yildiz Pekoz (Autor), Ozlem Akbal Dagistan (Autor), Hanan Fael (Autor), Meltem Culha (Autor), Aybige Erturk (Autor), Nur Sena Basarir (Autor), Gokben Sahin (Autor), Muge Serhatli (Autor), Gamze Cakirca (Autor), Saban Tekin (Autor), Leyla Semiha Sen (Autor), Mustafa Sevim (Autor), Lutfiye Mulazimoglu Durmusoglu (Autor), Berrak C. Yegen (Autor)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2. However, poor accumulation of favipiravir in lung tissue following oral administration has required an alternative method of administration that d...